Company Overview
IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also offers IDE849, a DLL3 antibody drug conjugate inhibitor for the treatment of SCLC and neuroendocrine carcinomas; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; IDE161, a poly ADP-ribose glycohydrolase inhibitor; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD; IDE397, a MAT2A inhibitor for MTAP-deleted tumors; IDE892, a PRMT5 inhibitor; IDE574 selectively inhibits KAT6/7 and is in Phase 1 dose escalation trial for patients with breast, lung, prostate, and colorectal cancers; IDE275 oral small molecule inhibitor of the helicase domain of the Werner protein (WRN) and is in a Phase 1 clinical trial. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Novartis, Biocytogen, Cancer Research UK, the University of Manchester, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and Les Laboratoires Servie. It also has a clinical collaboration agreement with AstraZeneca plc to evaluate IDE849, an antibody-drug conjugate; and clinical collaboration with Roche to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6505, Roche's Phase 1 pan-RAS inhibitor, in MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Why Investors Should Care
Revenue has grown at a 62.1% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $218.71M (+3024.4% YoY); net profit $-113.70M.
- Trailing 12 Months Year-on-year growth — revenue +3024.4%.
- 5-Year Trend Long-term compounding — revenue CAGR 62.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 62.11% |
| 1 Year: | 3,024.43% |
Stock Price Performance
| 1 Year: | +62.71% |
| 6 Months: | -0.27% |
| 3 Months: | +13.57% |
| 1 Month: | +26.78% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)57.88 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 62.1% over 5 years.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | IDYA IDEAYA Biosciences, Inc. R2K | 36.74 | -23.40 | $3.54B | 0.00% | -15.17% | -14.28% | 62.11% | - |
| 2 | LLY Eli Lilly and Company SPX | 1,156.63 | 41.13 | $1.03T | 0.60% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 247.02 | 28.66 | $594.63B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.11 | 119.08 | $431.29B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 418.52 | 31.54 | $380.08B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 123.61 | 34.82 | $305.29B | 2.82% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 168.37 | 26.10 | $261.12B | 1.87% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 535.29 | 29.40 | $198.93B | 0.35% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 358.32 | 24.92 | $193.39B | 2.80% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | 8.97M | 7.25M | 8.76M | 8.98M | 11.36M | 5.85M | 29.70M | 7.88M | 3.54M | 8.04M | 0 | 0 | 0 | - | - | 207.83M | - | 6.56M |
| Operating Income | - | -7.57M | -13.63M | - | -10.09M | -11.23M | -11.62M | - | -12.48M | -12.59M | -5.00M | -9.13M | -11.05M | -11.71M | -14.22M | -22.50M | 660.00K | -26.28M | -32.71M | -33.53M | -51.02M | -64.93M | -66.89M | -84.39M | -88.81M | 108.45M | - | -108.54M |
| Net Income | -5.74M | -7.00M | -13.05M | -8.56M | -9.57M | -10.66M | -10.97M | -10.78M | -12.04M | -12.39M | -4.93M | -9.02M | -10.95M | -11.58M | -14.01M | -22.06M | 1.61M | -23.64M | -27.93M | -27.44M | -39.57M | -52.77M | -51.82M | -72.18M | -77.49M | 119.24M | - | -98.54M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | -0.33 | -0.31 | -0.36 | -0.57 | 0.04 | -0.49 | -0.50 | -0.46 | -0.53 | -0.68 | -0.60 | -0.82 | -0.88 | 1.33 | - | -1.11 |
| R&D Expense | - | 6.43M | 12.54M | - | 8.00M | 8.86M | 8.92M | - | 9.03M | 8.60M | 10.03M | 11.57M | 14.98M | 15.50M | 19.66M | 22.80M | 22.37M | 27.86M | 29.18M | 33.70M | 42.80M | 54.53M | 57.15M | 70.89M | 74.23M | 82.99M | 86.60M | 95.73M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 0 | 19.54M | 27.94M | 50.93M | 23.39M | 7.00M | 218.71M |
| Operating Income | -14.44M | -36.42M | -44.27M | -35.34M | -50.27M | -62.50M | -134.43M | -326.98M | -159.31M |
| Net Income | -11.86M | -34.35M | -41.98M | -34.49M | -49.76M | -58.66M | -112.96M | -274.48M | -113.70M |
| Diluted EPS | - | - | - | -1.40 | -1.41 | -1.42 | -1.96 | -3.36 | -1.28 |
| R&D Expense | 12.38M | 31.75M | 34.32M | 39.70M | 58.16M | 89.54M | 129.51M | 294.67M | 314.70M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 96.54M | 113.00M | 298.27M | 381.35M | 387.97M | 649.32M | 1.12B | 1.11B |
| Total Equity | -4.13M | -15.74M | -48.95M | 100.40M | 198.27M | 301.51M | 349.45M | 621.09M | 1.06B | 1.02B |
| Cash & Equivalents | - | 5.96M | 20.50M | 34.07M | 72.04M | 92.05M | 68.63M | 157.02M | 84.38M | 112.83M |
| Total Liabilities | - | - | 7.10M | 12.60M | 100.00M | 79.83M | 38.51M | 28.23M | 64.94M | 86.39M |
| Current Liabilities | - | - | 5.41M | 6.94M | 38.64M | 45.16M | 31.72M | 27.10M | 46.07M | 58.81M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -12.22M | -27.62M | -39.31M | 55.46M | -55.78M | -87.17M | -115.22M | -247.58M | -71.10M |
| Investing Cash Flow | -8.93M | -63.18M | 2.27M | -146.24M | -69.67M | -33.40M | -158.46M | -502.56M | 69.98M |
| Financing Cash Flow | 17.49M | 105.38M | 50.61M | 128.75M | 145.45M | 97.17M | 362.72M | 677.55M | 29.78M |
| Capital Expenditure | -1.76M | -1.71M | -1.35M | -493.00K | -2.64M | -3.44M | -2.37M | -3.86M | -2.37M |
| Free Cash Flow | -13.98M | -29.33M | -40.67M | 54.97M | -58.42M | -90.62M | -117.59M | -251.44M | -73.47M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | -180.9% | -179.9% | -122.7% | -574.9% | -4,671.1% | -72.8% |
| Net Margin % | - | - | - | -176.6% | -178.1% | -115.2% | -483.0% | -3,921.1% | -52.0% |
| ROE % | 75.4% | 70.2% | -41.8% | -17.4% | -16.5% | -16.8% | -18.2% | -25.9% | -11.1% |
| ROCE % | - | -40.0% | -41.7% | -13.6% | -15.0% | -17.5% | -21.6% | -30.3% | -15.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 14.99% | 13.17M | $481.51M |
| 2 | Blackrock Inc. | 9.61% | 8.44M | $308.60M |
| 3 | Janus Henderson Group PLC | 8.27% | 7.27M | $265.58M |
| 4 | Capital Research Global Investors | 5.88% | 5.16M | $188.75M |
| 5 | Baker Bros. Advisors, LP | 4.49% | 3.95M | $144.26M |
| 6 | State Street Corporation | 4.30% | 3.78M | $138.22M |
| 7 | Vanguard Capital Management LLC | 4.25% | 3.73M | $136.44M |
| 8 | Logos Global Management LP | 3.93% | 3.45M | $126.11M |
| 9 | Federated Hermes, Inc. | 3.40% | 2.99M | $109.19M |
| 10 | Adage Capital Partners GP L.L.C. | 3.21% | 2.82M | $103.21M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for IDYA
IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - PR Newswire
<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxONFZKZG5hRFNHSWM0M1E0YjJ1R0hrUXVIUFVLU1NPLU1sT29tdkZvVDVGdmZjak51b0RYc1hITW56RjdWcEhQYi1nbU9sbU52bXdQWDNOQnc3RkxFRXNHbkZLNkNzODEwNWNQTm4ycmY3QlF6allmMkJNdnNIRFczdU5WTWZrTzBDSTRpam…
Insider Sale: Chief Accounting Officer of $IDYA Sells 9,550 Shares - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxNRFBmSVRxdE43VmgxZGI4TmZkZ3BkM3MxOGFxczJmX0Naay02Uk1LVzBkTmt1THFXcU9xeDdlLVA2Tk1NenRWcUVmOFd0UWpWejJQXzdpQW5LZnlWTDkyVHA2dkJCRUp0WmRmbG1RV1RQOXdnd1E2X3FKd1d0LVpNbjBDMUFGVktadFNINV…
Is IDEAYA Biosciences, Inc. (IDYA) A Good Stock To Buy Now? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxQdEhSYV9uUndPVmx1UVVaZ2k2b3ZrU28xemhMMXVyRDZZWlZ0U0IteGFEUElEazE0NXJPVDVJZlBHc01EdjZRS09zVjFXWnd3eGpGZk90ZXhGN2E3R0Jub01mSUtjT1N4cG00eUthYWtCYU1UMGRWVW9vLW56YnM4VW9Va2d2ZVNwZi1mdk…
Insider Sale: Chief Accounting Officer of $IDYA Sells 9,550 Shares - Moomoo
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxOZU9DbmdFUVZWbEF0VWRWbTJfUlJjWmh3NEJhaWo0dUNJRHM3SUlNRjdQZlQweWktNUV1MVdFYkUwcUNjYzE4LW5LWlEweFEtWkNNN01lcGdSaE40Q2wtZWtVbEhzYnYtakgycUQyb3Y1ZzcxM0FUU00wa0R0WnFaOWxRYzNJYW5sYlo4eE…
IDEAYA Biosciences (IDYA) CAO exercises options, sells 9,550 pre-planned shares - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxObElSNFpVSHFoUVpaSE5udVpLcUZEMmg3cVJXMFlqOGFxTEhvdThoa2lXdnZ6SG5TYVdFOW03WGRBVnNma2M5eVYwMGwtQXhaWXY0NXFRZko5dmhvem1DMFJEOVJLa0xwSmhiRnIxQ3k2QkFyY0VwTkd2ZG94dWI3bHF6UVA4WVNXeTNCT2…
Nasdaq, S&P 500 Futures Slip As Hormuz Blockade Escalates Tensions: Why BATL, INTC, PLTR, IDYA Are On Traders' Radar Today - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi3AFBVV95cUxNWDhNMmY5RFZ3RGNZMjlWTkJzemtvWFRmcmctYmZLZE5qZVpaUjJSNmU4WjlRakp5cXU1bzlHMklOUDRXRmEya0NUOXV5ei1vRWxEM2dhakItVEdlRHVGYzVOX2J4Nm4ybnhmUVRyRXdMQXhBMXNkOUdXUHJ1TXRCSVhDbzFQODZ5RUg3c1…
IDYA — Frequently Asked Questions
What is the current share price of IDEAYA Biosciences, Inc. (IDYA)?
As of 2026-07-15 16:51 PDT, IDEAYA Biosciences, Inc. (IDYA) trades at $36.74 on NasdaqGS. Its 52-week range is $21.43 to $40.51.
What is the market capitalisation of IDYA?
IDEAYA Biosciences, Inc. (IDYA) has a market capitalisation of $3.54B on NasdaqGS.
What is the P/E ratio of IDYA?
IDYA trades at a trailing price-to-earnings (P/E) ratio of -23.40. The industry average P/E is 25.88. Its price-to-book (P/B) ratio is 3.43.
What is the return on equity (ROE) of IDYA?
IDYA has a return on equity (ROE) of -14.28%. Its return on capital employed (ROCE) is -15.17%.
Is IDYA a good stock to buy?
This page provides a data-driven analysis of IDEAYA Biosciences, Inc. (IDYA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.